Want to learn how clinical genomics dx are developed @MayoClinic? Hussam Al Kateb, Mayo Clinical Labs co-director of clinical genomics, shares how the world-renowned medical center develops LDTs, such as for gene fusions in solid tumors. insideprecisionmedicine.com/… via @Inside_PM
Time flies... last month was the 10th anniversary of the first base editing report, published in @Nature, led by Alexis Komor in the lab of @davidrliu.
A worthy excuse then to re-post this fun 60-minute interview with Alexis and @NicoleGaudelli on the origins of base editing.
Hoping the FBI doesn’t show up at my door in response to my @Inside_PM deep dive into the culling of FDA leadership, focusing on Makary’s resignation and the blocked publication of two COVID-19 vaccine safety studies accepted in medical journals.
insideprecisionmedicine.com/… via @Inside_PM
In the 2000s, @MattRVerse saw tech skyrocketing—except clinical dx. Then 2 tragic genetic diagnoses in his family changed it all. So, he founded @NateraGenetics & @myomeinc to enable preemptive medical intervention.
A rare mix: deep tech + deeply human.
insideprecisionmedicine.com/…
Richard Dawkins is the Rick Rubin of science…”I have no technical ability. I know nothing about [science]. I know what I like and what I don't like. I'm decisive about what I like and what I don't like."
How you know you're about to arrive at the 2026 @AACR conference (that's obviously in #SanDiego given the @Rivian...or the top-down on my own little vehicle 🫠)
Pig organs haven’t delivered long-term. But @eGenesisBio is redefining success: not as a cure, but a bridge to eligibility for human organs. CEO Mike Curtis breaks down recent pig kidney transplant cases & how they’re prepping for larger clinical trials.
shows.acast.com/67105af84872…
A key moment from Behind the Breakthroughs Ep. 37
@GrinsteinJ speaks with @Markus_Warmuth, MD, CEO of @MonteRosaTx, about using the cell’s own protein-disposal machinery to eliminate harmful proteins in cancer and autoimmune disease.
hubs.li/Q0484zHP0
In April 2024, Ricky Chu got the call no parent is ready for: his almost-5-year-old son Skyler had Hunter syndrome (MPS II), a rare genetic disease with no cure. Within weeks, baby brother Ollie was diagnosed too—launching the Chu family into a whirlwind of insurance battles, international travel, and a race against time for treatment. Today, after nearly a dozen trips to the U.K. and infusions of a first-in-human gene therapy, both boys are mobile, verbal, bilingual—and living proof that relentless hope can rewrite the odds.
There's a second side to the story, which goes back a decade before Ricky ever got the call. For over a decade, researcher Brian Bigger, clinicians Simon Jones and Rob Wynn (@MFTnhs), and Andrew McFadyen (The Isaac Foundation) have been in a battle to fund research, navigate clinical trials, and bring hope to children living with one of the rarest neurodegenerative diseases on the planet.
This feature was incredibly impactful and eye-opening for me as to the almost insurmountable battle for rare disease families and patients to get life-saving care.
insideprecisionmedicine.com/… via @Inside_PM